ArticleNature chemical biology2017
A combinatorial screen of the CLOUD uncovers a synergy targeting the androgen receptor.
Article in Nature chemical biology, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 25 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
25 citing papers in PubMed, 50 citations in OpenAlex.
- Metabolic reprogramming drives pancreatic β cell neogenesis from α cells.Nature chemical biology · 2026Article
- Development of a high-throughput screening platform for identification of functional BACH1 inhibitors reveals compounds with anti-invasive potential.Redox biology · 2026Article
- UniSyn: a multi-modal framework with knowledge transfer for anti-cancer drug synergy prediction.Genome biology · 2026Article
- PAIRWISE: Deep Learning-based Prediction of Effective Personalized Drug Combinations in Cancer.Research square · 2026Article
- KRAS mutated lung adenocarcinoma responds to pan-ERBB and Aurora kinase inhibitors.NPJ precision oncology · 2026Article
- Investigating the Therapeutic Potential and Molecular Mechanisms of Daphnetin: A Comprehensive Review.Recent patents on anti-cancer drug discovery · 2026Review
- A review of deep learning approaches for drug synergy prediction in cancer.npj drug discovery · 2025Review
- HIG-Syn: a hypergraph and interaction-aware multigranularity network for predicting synergistic drug combinations.Bioinformatics (Oxford, England) · 2025Article
- Augmented drug combination dataset to improve the performance of machine learning models predicting synergistic anticancer effects.Scientific reports · 2024Article
- Augmented drug combination dataset to improve the performance of machine learning models predicting synergistic anticancer effects.Research square · 2023Article
- SYNPRED: prediction of drug combination effects in cancer using different synergy metrics and ensemble learning.GigaScience · 2022Article
- Machine learning approaches for drug combination therapies.Briefings in bioinformatics · 2021Review
- Vitamin K-Dependent γ-Glutamyl Carboxylase in Sertoli Cells Is Essential for Male Fertility in Mice.Molecular and cellular biology · 2021Article
- Analysis framework and experimental design for evaluating synergy-driving gene expression.Nature protocols · 2021Article
- Anticancer drug synergy prediction in understudied tissues using transfer learning.Journal of the American Medical Informatics Association : JAMIA · 2021Article
- SYNERGxDB: an integrative pharmacogenomic portal to identify synergistic drug combinations for precision oncology.Nucleic acids research · 2020Article
- Repurposing screen identifies mebendazole as a clinical candidate to synergise with docetaxel for prostate cancer treatment.British journal of cancer · 2020Article
- Mapping the perturbome network of cellular perturbations.Nature communications · 2019Article
- DrugComb: an integrative cancer drug combination data portal.Nucleic acids research · 2019Article
- Drug combination sensitivity scoring facilitates the discovery of synergistic and efficacious drug combinations in cancer.PLoS computational biology · 2019Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
24 authors at 5 institutions in 5 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Approved drugs are invaluable tools to study biochemical pathways, and further characterization of these compounds may lead to repurposing of single drugs or combinations. Here we describe a collection of 308 small molecules representing the diversity of structures and molecular targets of all FDA-approved chemical entities. The CeMM Library of Unique Drugs (CLOUD) covers prodrugs and active forms at pharmacologically relevant concentrations and is ideally suited for combinatorial studies. We screened pairwise combinations of CLOUD drugs for impairment of cancer cell viability and discovered a synergistic interaction between flutamide and phenprocoumon (PPC). The combination of these drugs modulates the stability of the androgen receptor (AR) and resensitizes AR-mutant prostate cancer cells to flutamide. Mechanistically, we show that the AR is a substrate for γ-carboxylation, a post-translational modification inhibited by PPC. Collectively, our data suggest that PPC could be repurposed to tackle resistance to antiandrogens in prostate cancer patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.